NEW YORK (GenomeWeb News) — Cellzome has extended until June 2008 its research agreement with Novartis, the company said yesterday.
Under the terms of the partnership, Cellzome will continue to use its proteomics and pathway mapping experience to identify therapeutic and pharmacological targets to Novartis compounds.
Financial details of the arrangement were not disclosed, but Cellzome said there are “compound development options for both companies in exchange for licenses, milestone payments and royalties.”
The companies first entered their agreement in 2004 and renewed it last year. In 2005 Novartis made a “substantial equity investment” in the privately held company, Cellzome said